Symptoms and General Pathology

All Conditions

Colonic Polyps

Polyps

Pathological Conditions, Anatomical

Intestinal Polyps

Patients with an unexpected malignant colorectal polyp where a decision needs to be made concerning the management of care.

Historical data on the management of patients with an unexpected malignant colorectal polyp from February 2018 to the end of 2022 retrieved through the Danish Colorectal Cancer Group Database, the National Pathology database and the National Patient Register.

The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.

Shared Decision Making using a Patient Decision Aid.

Helene Würtz, MD

Karina D Steffensen, Prof PhD MD

Hans B Rahr, Prof Dr MD

Management of unexpected malignant colorectal polyps removed endoscopically can be challenging due to the risk of residual tumor and lymphatic spread. International studies have shown that in patients choosing surgical management instead of watchful waiting, 54-82% of bowel resections are without evidence of residual tumor or lymphatic spread. As surgical management entails risks of complications and watchful waiting management entails risks of residual disease or recurrence, a clinical dilemma arises when choosing a management strategy.

Shared decision making (SDM) is a concept that can be used in preference sensitive decision making to facilitate patient involvement, empowerment, and active participation in the decision making process.

This is a clinical multicenter, non-randomized, interventional phase II study involving Danish surgical departments planned to commence in the first quarter of 2024. The aim of the study is to examine whether shared decision making and using a patient decision aid (PtDA) in consultations affects patients' choice of management compared with historical data. The secondary aim is to investigate Patient Reported Experience Measures (PREMs) and Patient Reported Outcome Measures (PROMs) using questionnaire feedback directly from the patients.

The study is a clinical multicenter, non-randomized, interventional phase II study. Three to five departments of colorectal surgery in Danish hospitals will be invited to participate in the study.

The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp

The Impact of an In-consultation Patient Decision Aid on Treatment Choices and Outcomes of Management for Patients With an Unexpected Malignant Colorectal Polyp A Non-randomized Clinical Phase II Study

Score range 1-100. The higher the score, the better the quality of life.

Vejle Hospital

Neoplasms

Digestive System Diseases

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Pharmaceutical Solutions

All Drugs and Chemicals

Glycerol

Protective Agents

Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.

Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.

Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope

Endoscopic submucosal dissection

Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.

use of Orise Gel as lifting agent for endoscopic submucosal dissection

Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.

use of glycerol as lifting agent for endoscopic submucosal dissection

Arnaud Lemmers, MD,PhD

The EPSILON study aims to comparatively evaluate the submucosal injection using ORISETM gel and glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.

Traditionally, ESD requires the injection of some colloidal solution (glycerol, geloplasma, hydroxyethylstrach, etc.) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion. Alternatives to colloid-solution assisted ESD have also been developped: pocket creation method and saline-immersion ESD.

Recently, other colloidal solutions have arrived on the market, such as gel (ORISETM gel) in order to improve the lifting during ESD.Our preliminary experience using ORISETM gel as a lifting solution for ESD was unexpectedly favourable with few per-procedural bleeding, quick time and facility.

As the spread of ESD is closely associated to its easiness, procedure duration (itself associated to number of procedural bleedings and instruments change through the operating channel) and safety, we sought to study comparatively two submucosal solutions when conducting ESD in a specific population presenting gastric or rectal superficial lesions.

A multicentric, randomized, open label prospective study:

* All subjects with indications of gastric and rectal ESD undergo screening and baseline visit
* Informed consent is obtained when scheduling the ESD procedure
* Randomization is made at the time of the ESD procedure after confirmation of the indication
* ESD is performed using a 25 G needle, a dual-knife-J with glycerol (standard solution) or ORISETM gel in order to remove the lesion en-bloc. Additional saline injection through the electrosurgical knife will be left at the discretion of the endoscopist
* A follow-up visit is scheduled at 2-4 weeks

A computer-based block randomization scheme will be created using block randomization and stratifying by center and by organ type (stomach/rectum). Data will be collected through a printed CRFs and then anonymized and entered into a central web based secured platform.

EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection

EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection: a Randomized Controlled Multicentric Trial (EPSILON)

Number of per-procedural bleeding (+ severity scale: oozing / severe non pulsating/ severe pulsating)

Total hemostatic time (addition of each hemostasis time for each per-procedural bleeding)

Difficulty of the dissection (scale) (very easy / easy / moderately difficult / difficult / very difficult)

Amount of submucosal solution (glycerol or gel) used for ESD in ml

Combined use of saline through the knife during ESD (number and ml)

Number of needle injection dots during ESD (initially / during ESD)

Need to adjust electrosurgical settings during ESD

Clear visualisation of the plane of dissection during ESD (scale). The scale will be defined according the endoscopists evaluation of the delineation between the submucosa ad the underlying muscular layer:

* Very-good visualization: clear delineation between the two layers with clear visualization of the blood vessels.
* Good visualization: mostly clear delineation between the two layers, but with blurred regions
* Bad visualization: delineation between the two layers is unclear (i.e.:

fibrosis)

Rate of en-bloc dissection (defined as endoscopic resection of the targeted area in one bloc)

Rate of complete endoscopic resection (defined as endoscopic evaluation of complete removal of the targeted area in the treated organ)

Quality assessment of the pathological specimen (absolute measure of the depth of resected submucosa on the specimen, rate of clear (horizontal and vertical) margins)

Adverse events:

* Per-procedural (incidence of all adverse technical events during the procedure)
* Early (clinical and laboratory at 24 h post procedure according to CTCAE v 5.0)
* Late (clinical at 2-3 weeks follow-up)

Increase the dissection speed of the ESD procedure (defined as the dissected surface (mm2)/ESD duration (min). The dissected surface is defined as maximal diameter of specimen (mm) x perpendicular minimal diameter of specimen (mm) measured on ex-vivo pinned stretched specimen onto a cork. ESD duration is defined as the time from first submucosal injection to final cut time.

Total procedure duration (from scope insertion to scope retrieval) (min)

Erasme University Hospital

MD, PhD, Professor, Head of Clinic, Endoscopy Unit

Heart and Blood Diseases

Adenoma

Fistula

Hemorrhoids

Fissure in Ano

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Rectal Diseases

Intestinal Diseases

Vascular Diseases

Anus Diseases

Micronutrients

Herbal and Botanical

Silicon

Cola

In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.

In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.

Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.

Coloshield

In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.

Control

Daniel C Steinemann, MD

In various transanal and anal procedures it is desirable to clean the operating field from stool contamination. Thus mechanical bowel preparation is not well tolerated by patients. Enema does not provide sufficient effect. By the use of Coloshield a rectal washout might be performed and enable a clean operating field. In this randomized controlled trial the macroscopic contamination of the rectum with and without Coloshield is compared using the Boston Bowel Preparation Score (0-3).

Trial on Use of Coloshield in Transanal and Anal Surgery

Randomized Controlled Trial on Practicability of Coloshield in Transanal and Anal Surgery

The position of the deployed Coloshield at beginning of surgery and after 30 minutes is measured by rigid rectoscopy in cm from anal verge. Any slippage of the device during surgery is documented.

After removal of Coloshield by rigid rectoscopy any bleedings or tear injuries in the rectal mucosa (caused by Coloshield) are noted. It will be documented if there are bleedings or tear injuries or not, and if the exact number of bleedings and tear injuries.

The pain level on a VAS score from 0 (no pain) to 10 (strongest) 6 hours, 24 hours and 48 hours after surgery are documented.

Daniel Steinemann, MD

Sponsor-Investigator

Inflammatory Bowel Diseases

Prolapse

Diverticulitis

Rectal Prolapse

Gastroenteritis

Diverticulum

Diverticular Diseases

Pelvic Organ Prolapse

All patients who undergo a single port robot colorectal surgery.

Single Port Robotic Colorectal Surgery

John H Marks, MD

The purpose of this study is to evaluate the safety and feasibility of using the Single Port (SP) robot (daVinci, Intuitive Surgical) to perform single port robotic colon surgery and transanal robotic surgery. The hypothesis of the study is that the SP robot will prove a safe effective modality to perform these procedures.

In the colorectal arena, the robotic approach for benign and malignant disease is well established, with a great deal of literature generated regarding the safety and benefits of a colorectal robotic approach for benign and malignant disease. The section of colorectal surgery at the Lankenau Medical Center has been an active and robust contributor to surgical literature on laparoscopic surgery, robotic colorectal surgery, and single port laparoscopic surgery. Its one investigator has been involved in the development of clinical applications to the single port robotic platform where this has been utilized in cadaver work that has been published. Recently, the SP robot has gone through FDA clearance and is now available for clinical utilization. The FDA approval is for urologic surgery. The SP robot will be utilized in the same fashion to perform the same colorectal operations that the investigators have been performing with multiple port placements in the past to accomplish robotic surgery in a single port platform in the colorectal arena. The principal investigator has worked on the SP robot over the past 3 years with extensive cadaver experience to develop its safe application in the colorectal field. This study will entail a collection of demographics, preoperative, perioperative and postoperative outcomes of the patients into a database to follow this, report on the outcomes, and notably answer questions to demonstrate the feasibility and safety of this approach in colorectal patients.

Feasibility and Safety of Single Port Robot in Colorectal Procedures

Calculating the percentage of cases successfully performed using the SP robot, without conversion.

Measuring the post-operative morbidity and mortality will be used to evaluate the safety of the SP robot.

Validated questionnaire will be administered to assess the quality of life of patients:

- RAND 36 item Health Survey (by the RAND corporation): All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. This validated questionnaire asks patients to rate their own health and rate their ability to perform a variety of everyday activities using the same scale.

Validated questionnaire will be administered to assess the patients satisfaction with surgery Patient Scar Assessment Questionnaire (PSAQ)- The PSAQ consists of 5 subscales: Appearance (# of items-9; min-9; max-36), Consciousness (#-6; min-6; max-24), Satisfaction with Appearance (#-8; min-8; max-32) and Satisfaction with Symptoms (#-5; min-5; max-20). Higher scores define more favorable scar appearance, less consciousness of one's scar, increased satisfaction with appearance and symptoms. The scales for each of these subsections is the same; however, min and max scores differ due to differing numbers of questions in each section.

- Quality of Recovery 40 questionnaire: score range: 40-200. Higher values represent better outcomes. The validate questionnaire measure quality of recovery by evaluating patients' comfort, emotions, physical independence, and support using the same scale.

Body image questionnaire- 13 items total; min score-13 and max score-100. Higher scores correlate to more favorable body image. In reflecting on their own body image, patients are then asked to rate how likely they would be to undergo a laparoscopic, open, versus single port surgery given their experience. These variables are measured on the same scale.

Marks Colorectal Surgical Associates

Chief of Colorectal Surgery

Colonic Diseases

Colonic Diseases, Functional

Colonic Neoplasms

Intestinal Neoplasms

Colorectal Neoplasms

Adults 45 years of age and older who are at average risk of developing colorectal cancer and eligible for a screening colonoscopy

The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.

Next-Gen CRC Screening Test

The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.

The CRC DRAW study is a prospective, multi-center, observational study to validate the Next-Gen CRC Screening test for the detection of CRC. The study will collect blood samples from average-risk participants scheduled for screening colonoscopies.

Blood specimens will be de-identified and used to validate the performance characteristics of the Next-Gen CRC Screening Test. Blood samples may also be used for future research and development, feasibility and validation.

CRC Detection Reliable Assessment With Blood

Prospective, Multi-center Observational Study for the Clinical Validation of the Next Generation Test for Blood-based Screening of Colorectal Cancer

Epigenomics, Inc

Rectal Neoplasms

Treatment of rectal lesions with UNI-VEC

Ariadna Camps, Biomedical engineering

Carlos Álvarez, Medicine

Salvadora Delgado, Medicine

José F Noguera, Medicin

José F Noguera, Medicine

Alba Gómez, Medicine

Olga Maseda, Medicine

Raquel Sánchez, Medicine

Marta Jiménez, Medicine

Mario Álvarez, Medicine

Pedro Parra, Medicine

Javier Sánchez, Medicine

Blas Flor, Medicine

The aim of the clinical trial is to investigate whether the use of a new multichannel endoscopic transanal access device (named UNI-VEC) is safe and effective in the resection of a rectal polyp or tumor that sits in the distal part of the colon (up to about 20 cm from the anal margin). This is the first study to test the device in humans, after proving its good performance in preclinical development (preclinical development has included functional laboratory tests and an animal trial).

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device

The device must allow the removal of polyps with a minimum size of 2 cm (maximum diameter of the removed polyp measured in mm) in the rectum.

Anorectal hemorrhagic events for each patinet will be recorded in a table and the number of events will be counted.

The number of injuries to the anorectal canal and perianal region will be recoreded in a table and then the total number of injuries will be counted.

Anorectal continence will be assesed for each Participant with the Wexner Score

Vecmedical Spain, S.L.

Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the intervention group where they are provided access to an application which indicates recommended timing of follow-up colonoscopy given values for various entered factors. In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). Access to the application will be password-protected, thereby avoiding exposure of the non-intervention group to the application. The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.

Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the group where they are not provided access to the application (control group).

There is a very high utilization of colonoscopy at both shorter and longer time intervals than the recommended guidelines. Investigators have developed a clinical support tool in which the characteristics of the patients can be inputted and the guideline recommended time interval for surveillance colonoscopy is then provided. This tool uses the recommendations from the current North American national guidelines. The tool has been developed as a web-based application as well as a smart phone application.

Access to colonoscopy web app

Harminder Singh, MD

Overall Objective: To optimize timing of surveillance colonoscopy.

Principal research question and specific aims: To assess the impact of access to a hand-held application on the timing of surveillance colonoscopy. To assess whether access to the tool improves adherence to recommended guidelines for follow-up colonoscopy intervals.

Colonoscopy is commonly used for surveillance of patients with high risk of developing colorectal cancer, including those with family history of colorectal cancer and those with colorectal polyps. The recommended timing of surveillance colonoscopy varies by the estimated risk for development of colorectal cancer. The estimated risk varies by family history of colorectal cancer (number of affected individuals, age of the persons affected with CRC) and characteristics of the colorectal polyps (size, number, and histology of colorectal polyps (tubular or villous; high grade or low-grade dysplasia; sessile serrated polyp, sessile serrated polyp with dysplasia, hyperplastic polyp or traditional serrated adenomas). Guidelines take all of these factors into account in the recommendations for follow-up colonoscopy and hence are difficult to recall for the busy clinicians. Colonoscopy surveillance is frequently performed at shorter or longer than the recommended time intervals. The investigators have developed a smart phone application in which the characteristics of the patients can be inputted and the tool provides the recommended time interval for surveillance colonoscopy, based on North American guidelines. The investigators are proposing a pilot randomized trial to determine sample size estimates for a larger trial to assess the utility of this application in clinical practice.

Study design and intervention: This will be a cluster randomized controlled trial in which individual endoscopy physicians (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to one of two groups: A) provided access to the application (intervention group) or B) not provided access to the application (control group). In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.

Intervention: Access to the application which will be available both as a web-based as well as a smart phone application.

Setting: Colonoscopies included in the study will be those performed in the Winnipeg endoscopy units.

A research assistant will extract data from medical records maintained by the hospitals and physicians privately. Individual cases of colonoscopies will be identified through the city-wide endoscopy program database. Study data will be collected and managed using the REDCap (Research Electronic Data Capture) electronic data capture tools hosted at the University of Manitoba.

Concealment of Allocation and Randomization: Randomization will be performed after the endoscopy physician consent and enrollment into the study. A computer generated randomization sequence will used in blocks of eight. Stratification for surgical and gastroenterology endoscopy physician will be performed as there might be differential adherence to recommendations by speciality of training.

Blinding: Randomization will be performed and the application distributed by study personnel different than those involved in data extraction from medical records so that the person extracting the data remains blinded to the randomized group assignment.

Patient consent: Patients will not be approached by the study investigators and will get routine care decided by their physicians. Information on recommendations will be extracted from medical records retrospectively; hence, patient consent will not be required.

Duration of treatment and duration of follow-up: This is a cross-sectional study of those undergoing colonoscopy with no follow-up after any pathology is reported.

Outcomes: The primary outcome of analysis will be congruence (agreement) of the colonoscopy physician recommendation with the guideline recommendation.

Endoscopy physician recommendations will be determined from review of the medical records (endoscopy reports and letters/notes in the medical charts). Listing of colonoscopies performed by each enrolled colonoscopy physician will be obtained from the centralised common endoscopy reporting system. Absence of documented recommendations will be considered an incongruent recommendation in the primary analysis and excluded in a sensitivity analysis.

Medical records will be reviewed to obtain the history relevant to determining the timing of surveillance (characteristics of polyps, family history, inclusion and exclusion criteria). Absence of documented relevant history will be considered an incongruent recommendation in the primary analysis and excluded in a sensitivity analysis.

Secondary outcomes will be collected by a survey distributed to the group of endoscopy physicians that were provided the app to determine their opinions about the app. The survey will inquire about ease of use, perception of reliability, likelihood of future use, whether the app provided helpful information and how often they used the app and when. Percentage responses will be tabulated for this descriptive outcome. Investigators will also include open-ended questions about any desired changes to the app.

Another secondary outcome will be the proportion of cases which have a documented recommendation.

Similarly, in this pilot study, the investigators will assess the proportion of the medical records which have complete information (family history of colorectal cancer/polyps, different polyp characteristics) required to make surveillance colonoscopy recommendations as per the guidelines.

This will be a cluster randomized controlled trial in which individual endoscopy physicians (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to one of two groups: A) provided access to the application (intervention group) or B) not provided access to the application (control group). The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.

Randomization will be performed after the endoscopy physician consent and enrolment into the study. A computer generated randomization sequence will used in blocks of eight. Stratification for surgical and gastroenterology endoscopy physician will be performed as there might be differential adherence to recommendations by specialty of training.Randomization will be performed and the application distributed by study personnel different than those involved in data extraction from medical records so that the person extracting the data remains blinded to the randomized group assignment. Patients of participating physicians will not require blinding as they will not be approached by the study investigators and will get routine care decided by their physicians.

Optimizing Timing of Follow-up Colonoscopy

Optimizing Timing of Follow-up Colonoscopy: A Pilot Cluster Randomized Trial to Test the Utility of a Knowledge Translation Tool

Study findings will be disseminated via presentations at professional forums and published in a peer-reviewed journal.

No specific feedback will be provided to individual participants as we will perform and report aggregate analysis.

% of patients whose recommended colonoscopy frequency is in agreement with guideline recommendation based on patient factors and colonoscopy findings'

graded on an ordinal scale (strongly disagree, disagree, neutral, agree, strongly agree), N/A - Have not used app)

Ease of use graded on an ordinal scale (strongly disagree, disagree, neutral, agree), strongly agree, N/A - Have not used app)

graded on an ordinal scale (very familiar, familiar, unsure, new, very new, N/A - Have not used app)

graded on an ordinal scale (every day, every week, every month, less than once a month, did not use it)

graded on an ordinal scale (every day, every week, did not use it)

graded on an ordinal scale (never, less than 5%, more than 5% but less than 50%, more than 50%, N/A - have not used the app)

graded on an ordinal scale (very likely, likely, neutral, not likely, very unlikely )

graded on an ordinal scale (difficult to use, not helpful, too time consuming, other)

% of patients with a documented recommendation

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp	NCT05776381	Shared Decision... Colonic Polyp Decision Aids Rectal Polyp Colorectal Poly... Colorectal Canc...	Shared Decision...	18 Years -	Vejle Hospital
EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection	NCT04977401	Early Gastric C... Rectal Polyp	Endoscopic subm... use of Orise Ge... use of glycerol...	18 Years -	Erasme University Hospital
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp	NCT05776381	Shared Decision... Colonic Polyp Decision Aids Rectal Polyp Colorectal Poly... Colorectal Canc...	Shared Decision...	18 Years -	Vejle Hospital
Trial on Use of Coloshield in Transanal and Anal Surgery	NCT02579330	Fistula-in-ano Rectal Polyp Rectal Adenoma Hemorrhoids Anal Fissure	Coloshield Control	18 Years -	Cantonal Hosptal, Baselland
EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection	NCT04977401	Early Gastric C... Rectal Polyp	Endoscopic subm... use of Orise Ge... use of glycerol...	18 Years -	Erasme University Hospital
Feasibility and Safety of Single Port Robot in Colorectal Procedures	NCT03700593	Colon Cancer Colon Polyp Rectal Cancer Diverticulitis Prolapse, Recta... Rectal Polyp Inflammatory Bo...	Single Port Rob...	18 Years - 95 Years	Marks Colorectal Surgical Associates
CRC Detection Reliable Assessment With Blood	NCT05551052	Colorectal Canc... Adenomas Colon Colon Cancer Rectal Cancer Colon Neoplasm Colon Lesion Colon Disease Colon Polyp Polyps Adenoma Rectal Diseases Rectal Polyp Gastrointestina... Intestinal Neop... Colonic Disease... Intestinal Dise...	Next-Gen CRC Sc...	45 Years -	Epigenomics, Inc
Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device	NCT06286956	Rectal Polyp Rectal Polyps Rectal Lesion Sessile Colonic... Pedunculated Co...	Treatment of re...	18 Years -	Vecmedical Spain, S.L.
Optimizing Timing of Follow-up Colonoscopy	NCT04889352	Colo-rectal Can... Colon Polyp Colonic Polyp Rectal Polyp Polyp of Colon Polyp Rectal Polyps	Access to colon...	50 Years - 75 Years	University of Manitoba

Spots Global Cancer Trial Database for rectal polyp

Every month we try and update this database with for rectal polyp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.